Boston, MA – October 28, 2026 – For nascent biotechnology companies poised to translate groundbreaking scientific discoveries into life-changing therapies, the transition from preclinical research to clinical trials represents a monumental leap. This critical juncture demands not only robust scientific validation but also a strategic operational framework, with the selection of a competent Contract Research Organization (CRO) emerging as a paramount determinant of success. Scott Sawicki, Senior Director of Strategic Sourcing and Vendor Management at Centessa Pharmaceuticals, a company recently acquired by Eli Lilly and Company in June 2026, shared invaluable insights on this complex landscape at the 2026 Outsourcing in Clinical Trials (OCT) New England conference. His expertise, forged through extensive experience in big pharma, innovative biotech, and within the CRO sector itself, offers a compelling roadmap for early-stage drug developers navigating the often-treacherous waters of clinical outsourcing.
n
The Crucial Nexus: Why CROs Matter for Emerging Biotechs
n
The journey from a promising molecule to a patient-ready drug is a protracted and resource-intensive endeavor. For smaller biotechs, particularly those embarking on their inaugural clinical trial, the financial and operational burdens can be overwhelming. This is where the strategic engagement of a CRO becomes not merely beneficial, but often indispensable. Sawicki underscored that the right CRO partner can serve as an extension of the biotech’s internal team, providing the specialized expertise, infrastructure, and regulatory acumen necessary to execute a complex clinical program efficiently and compliantly.
n
"For emerging biotechs, the decision to partner with a CRO is a fundamental one," Sawicki explained during a Q&A session with Clinical Trials Arena reporter Frankie Fattorini. "It’s about more than just offloading tasks; it’s about leveraging specialized capabilities that you may not possess internally, especially at the early stages. A well-chosen CRO can accelerate timelines, mitigate risks, and ultimately, increase the probability of a successful clinical outcome."
n
The implications of a suboptimal CRO selection can be far-reaching, leading to costly delays, compromised data integrity, and even the premature termination of promising drug candidates. Conversely, a synergistic partnership can unlock new efficiencies, provide access to critical patient populations, and ensure adherence to the stringent regulatory standards governing clinical research.
n
A Chronology of Strategic Engagement: From Inception to Execution
n
Sawicki’s advice resonated deeply with attendees at the OCT New England conference, a prominent gathering focused on optimizing the outsourcing of clinical development activities. His perspective emphasizes a phased approach to CRO engagement, beginning long before the first patient is enrolled.
n
1. Early-Stage Assessment and Planning (Pre-IND/CTA Submission): Even at the preclinical stage, biotechs should begin to identify potential CRO partners. This proactive approach allows for thorough due diligence and the development of a robust understanding of the CRO landscape. Key considerations at this stage include:
n
- n
- Therapeutic Area Expertise: Does the CRO have a proven track record in the specific disease area of the biotech’s drug candidate?
- Regulatory Understanding: Does the CRO possess deep knowledge of the regulatory requirements in the target geographies (e.g., FDA in the US, EMA in Europe)?
- Scientific Acumen: Can the CRO’s scientific team contribute meaningfully to study design and protocol development?
- Financial Stability: Is the CRO financially sound and capable of undertaking a multi-year clinical program?
n
n
n
n
n
2. Protocol Development and Vendor Selection (Pre-Trial Initiation): As the biotech moves closer to regulatory submission (e.g., Investigational New Drug (IND) or Clinical Trial Application (CTA)), the CRO selection process intensifies. Sawicki highlighted the importance of collaborative protocol development, where the CRO’s input can optimize feasibility, patient recruitment strategies, and data collection. This phase involves:
n
- n
- Detailed Scope of Work Definition: Clearly outlining all services required, from site selection and patient recruitment to data management and biostatistics.
- Request for Proposal (RFP) Process: Developing a comprehensive RFP that solicits detailed proposals from shortlisted CROs, covering scientific approach, operational plan, timelines, and budget.
- Cross-Functional Evaluation: Involving scientific, clinical operations, regulatory, and procurement teams in the evaluation process.
n
n
n
n
3. Trial Execution and Oversight (During the Trial): Once a CRO is selected and contracts are in place, effective oversight and communication become paramount. Sawicki stressed the need for a strong project management framework and regular, transparent communication channels. This stage involves:
n
- n
- Establishing Key Performance Indicators (KPIs): Defining measurable metrics for success, such as patient recruitment rates, data query resolution times, and site performance.
- Regular Performance Reviews: Conducting periodic meetings to assess progress against KPIs, address challenges, and make necessary adjustments.
- Data Integrity Assurance: Implementing robust quality control measures to ensure the accuracy and reliability of clinical trial data.
n
n
n
n
4. Post-Trial Analysis and Future Planning: The conclusion of a clinical trial is not an endpoint but a stepping stone. Sawicki advised biotechs to conduct a thorough post-trial review of their CRO partnership, identifying lessons learned and areas for improvement for future studies.
n
Supporting Data: The Evolving Landscape of Clinical Outsourcing
n
The decision to outsource clinical trials is not unique to emerging biotechs. The global CRO market has witnessed substantial growth, driven by increasing complexity in drug development, rising R&D costs, and the growing demand for specialized expertise. Data from various market research firms consistently show a robust upward trajectory for the CRO industry. For instance, projections often indicate the global CRO market reaching hundreds of billions of dollars in the coming years, with significant contributions from small and mid-sized biotechs.
n
This growth is fueled by several key trends:
- Increasingly Complex Trials: Modern clinical trials involve sophisticated endpoints, advanced imaging techniques, and complex patient stratification, requiring specialized CRO capabilities.
- Globalization of Clinical Research: Conducting trials across multiple international sites necessitates CROs with global networks and regulatory expertise.
- Focus on Data Analytics and Real-World Evidence: The increasing importance of data analytics and the integration of real-world evidence (RWE) into clinical development require CROs with strong data management and analytical capabilities.
- Technological Advancements: The adoption of decentralized clinical trials (DCTs), artificial intelligence (AI) in data analysis, and digital health tools are transforming how trials are conducted, and CROs are at the forefront of this adoption.
Sawicki’s insights align with these market dynamics, emphasizing that biotechs must seek CROs that are not only capable of executing traditional trial activities but are also forward-thinking and adaptable to the evolving technological and regulatory landscape.
Official Responses and Industry Perspectives
While specific "official responses" from individual biotechs or CROs to Sawicki’s general advice are not publicly documented, the sentiment expressed at the OCT conference and in industry publications reflects a broad consensus. Industry leaders frequently emphasize the strategic importance of CRO partnerships.
For example, organizations like the Association of Clinical Research Organizations (ACRO) consistently advocate for strong, collaborative relationships between sponsors and CROs. Their publications and conferences often highlight best practices in vendor management, risk-sharing models, and the adoption of innovative technologies.
Eli Lilly and Company, having recently acquired Centessa Pharmaceuticals, is a major player in the pharmaceutical industry that heavily utilizes CROs for its extensive clinical development programs. Their strategic decisions regarding outsourcing are closely watched, and Sawicki’s advice, coming from a Centessa executive operating under the Lilly umbrella, carries significant weight. Lilly’s continued investment in both internal capabilities and external partnerships with CROs underscores the dual-pronged approach often adopted by large pharmaceutical companies.
Implications for the Future of Drug Development
Scott Sawicki’s guidance offers profound implications for the future of drug development, particularly for the burgeoning biotech sector. The era of the lone biotech struggling to navigate the complexities of clinical trials independently is rapidly giving way to a model of strategic collaboration.
1. Democratization of Clinical Development: By providing access to essential expertise and infrastructure, CROs empower smaller biotechs to compete on a more level playing field with larger pharmaceutical companies. This can lead to a more diverse pipeline of innovative therapies reaching patients faster.
2. Accelerated Innovation: Efficiently managed clinical trials, facilitated by experienced CROs, can significantly shorten the drug development lifecycle. This acceleration is crucial for addressing unmet medical needs and bringing life-saving treatments to market sooner.
3. Enhanced Quality and Compliance: CROs, with their specialized focus and established quality management systems, can help ensure that clinical trials are conducted to the highest standards of quality and regulatory compliance, thereby safeguarding patient safety and data integrity.
4. Strategic Specialization: The increasing complexity of drug development necessitates specialized expertise. Biotechs can leverage CROs to gain access to niche therapeutic area knowledge, advanced statistical methodologies, or specific regulatory insights, rather than attempting to build all these capabilities internally.
5. The Rise of the "Virtual Pharma": The effective outsourcing of clinical operations contributes to the rise of the "virtual pharma" model, where companies can maintain a lean core team while relying on external partners for the execution of most development activities. This can lead to more agile and cost-effective operations.
Sawicki’s core message is clear: for emerging biotechs aspiring to make their mark on the clinical landscape, the judicious selection and strategic management of CRO partners are not mere operational considerations; they are foundational pillars upon which clinical success and, ultimately, patient benefit will be built. As the biotechnology sector continues its rapid evolution, the insights shared by leaders like Scott Sawicki will remain indispensable for navigating the path from scientific promise to therapeutic reality.
